Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
72High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07383441CT.gov Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | — | Recruiting | — | — | — |
NCT07494435CT.gov Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC | — | Not Yet Recruiting | — | — | — |
NCT07620574CT.gov Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | — | Not Yet Recruiting | — | — | — |
NCT07188896CT.gov A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) | — | Recruiting | — | — | — |
NCT07510334CT.gov VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma | — | Recruiting | — | — | — |
NCT07128680CT.gov Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer | — | Recruiting | — | — | — |
NCT07405164CT.gov Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) | — | Recruiting | — | — | — |
NCT06863311CT.gov Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC | — | Recruiting | — | — | — |
NCT07233668CT.gov Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC | — | Not Yet Recruiting | — | — | — |
NCT07223424CT.gov Patient Preference for Subcutaneous vs. Intravenous Immune Therapy | — | Recruiting | — | — | — |
Show 107 more trialsShow fewer
NCT07028125CT.gov Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma | — | Recruiting | — | — | — |
NCT06866262CT.gov Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial | — | Recruiting | — | — | — |
NCT06934057CT.gov Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma | — | Recruiting | — | — | — |
NCT06601296CT.gov Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer | — | Recruiting | — | — | — |
NCT06362369CT.gov A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | — | Recruiting | — | — | — |
NCT06284564CT.gov A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) | — | Active Not Recruiting | — | — | — |
NCT06399419CT.gov CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer | — | Recruiting | — | — | — |
NCT06345183CT.gov Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients | — | Completed | — | — | — |
NCT06053658CT.gov Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma | — | Recruiting | — | — | — |
NCT06047379CT.gov Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | — | Recruiting | — | — | — |
NCT06034860CT.gov Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | — | Terminated | — | — | — |
NCT06049576CT.gov Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma | — | Active Not Recruiting | — | — | — |
NCT05928806CT.gov Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial | — | Suspended | — | — | — |
NCT05817903CT.gov Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients | — | Recruiting | — | — | — |
NCT05188118CT.gov Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma | — | Recruiting | — | — | — |
NCT05501054CT.gov Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. | — | Active Not Recruiting | — | — | — |
NCT05327686CT.gov Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | — | Recruiting | — | — | — |
NCT05678673CT.gov Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | — | Active Not Recruiting | — | — | — |
NCT05361720CT.gov Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study | — | Recruiting | — | — | — |
NCT05048212CT.gov A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases | — | Recruiting | — | — | — |
NCT04913025CT.gov REduced Frequency ImmuNE Checkpoint Inhibition in Cancers | — | Unknown | — | — | — |
NCT04904302CT.gov Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer | — | Terminated | — | — | — |
NCT05354102CT.gov A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 | — | Unknown | — | — | — |
NCT05148546CT.gov Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer | — | Active Not Recruiting | — | — | — |
NCT05239533CT.gov Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer | — | Active Not Recruiting | — | — | — |
NCT05263050CT.gov Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors | — | Recruiting | — | — | — |
NCT05176483CT.gov Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | — | Recruiting | — | — | — |
NCT05122546CT.gov CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | — | Active Not Recruiting | — | — | — |
NCT04987203CT.gov Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma | — | Completed | — | — | — |
NCT04902040CT.gov Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | — | Terminated | — | — | — |
NCT04413123CT.gov Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | — | Active Not Recruiting | — | — | — |
NCT04495257CT.gov A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) | — | Completed | — | — | — |
NCT04540705CT.gov A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread | — | Completed | — | — | — |
NCT04088500CT.gov A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma | — | Terminated | — | — | — |
NCT04429321CT.gov Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary | — | Terminated | — | — | — |
NCT04203901CT.gov Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma | — | Terminated | — | — | — |
NCT04107168CT.gov Microbiome Immunotherapy Toxicity and Response Evaluation | — | Unknown | — | — | — |
NCT04322955CT.gov CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition | — | Active Not Recruiting | — | — | — |
NCT04074967CT.gov Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | — | Active Not Recruiting | — | — | — |
NCT04142931CT.gov Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors | — | Unknown | — | — | — |
NCT04090710CT.gov SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer | — | Active Not Recruiting | — | — | — |
NCT04134182CT.gov Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment. | — | Unknown | — | — | — |
NCT03937219CT.gov Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | — | Active Not Recruiting | — | — | — |
NCT03873402CT.gov A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | — | Active Not Recruiting | — | — | — |
NCT03793166CT.gov Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | — | Active Not Recruiting | — | — | — |
NCT03991130CT.gov High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma | — | Terminated | — | — | — |
NCT03798626CT.gov Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | — | Completed | — | — | — |
NCT03829111CT.gov CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer | — | Completed | — | — | — |
NCT03866382CT.gov Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | — | Recruiting | — | — | — |
NCT03872947CT.gov A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03562507CT.gov Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma | — | Terminated | — | — | — |
NCT03647163CT.gov Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03829436CT.gov TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | — | Completed | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03758781CT.gov IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | — | Completed | — | — | — |
NCT03589339CT.gov NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | — | Active Not Recruiting | — | — | — |
NCT03595124CT.gov A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) | — | Active Not Recruiting | — | — | — |
NCT03729245CT.gov A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) | — | Terminated | — | — | — |
NCT03228667CT.gov QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT03655613CT.gov APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC | — | Terminated | — | — | — |
NCT03633110CT.gov Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | — | Completed | — | — | — |
NCT03635892CT.gov A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma | — | Active Not Recruiting | — | — | — |
NCT03552380CT.gov Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma | — | Terminated | — | — | — |
NCT03502330CT.gov APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | — | Completed | — | — | — |
NCT03149159CT.gov Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab | — | Withdrawn | — | — | — |
NCT03435640CT.gov REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies | — | Terminated | — | — | — |
NCT03511391CT.gov CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors | — | Completed | — | — | — |
NCT03311334CT.gov A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03274258CT.gov Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma | — | Terminated | — | — | — |
NCT03297593CT.gov Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma | — | Completed | — | — | — |
NCT03075423CT.gov Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC | — | Completed | — | — | — |
NCT03203473CT.gov Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) | — | Active Not Recruiting | — | — | — |
NCT03177239CT.gov Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) | — | Unknown | — | — | — |
NCT03229278CT.gov Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | — | Completed | — | — | — |
NCT03190174CT.gov Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | — | Completed | — | — | — |
NCT03126331CT.gov Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab | — | Completed | — | — | — |
NCT03141177CT.gov A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | — | Active Not Recruiting | — | — | — |
NCT03138512CT.gov A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney | — | Completed | — | — | — |
NCT03172754CT.gov Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma | — | Active Not Recruiting | — | — | — |
NCT03050060CT.gov Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer | — | Terminated | — | — | — |
NCT03117309CT.gov Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma | — | Completed | — | — | — |
NCT03015740CT.gov Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer | — | Completed | — | — | — |
NCT03136627CT.gov Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC | — | Completed | — | — | — |
NCT02989714CT.gov Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer | — | Completed | — | — | — |
NCT03065179CT.gov SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients | — | Completed | — | — | — |
NCT03029780CT.gov An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma | — | Completed | — | — | — |
NCT02982954CT.gov A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer | — | Completed | — | — | — |
NCT02983045CT.gov A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors | — | Completed | — | — | — |
NCT02899078CT.gov Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer | — | Completed | — | — | — |
NCT03115801CT.gov A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | — | Terminated | — | — | — |
NCT02917772CT.gov Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma | — | Completed | — | — | — |
NCT02718066CT.gov Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02526017CT.gov Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers | — | Completed | — | — | — |
NCT02496208CT.gov Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | — | Active Not Recruiting | — | — | — |
NCT02419495CT.gov Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT02423954CT.gov Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) | — | Terminated | — | — | — |
NCT02335918CT.gov A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | — | Completed | — | — | — |
NCT02293980CT.gov A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | — | Active Not Recruiting | — | — | — |
NCT02210117CT.gov Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery | — | Active Not Recruiting | — | — | — |
NCT02231749CT.gov Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) | — | Completed | — | — | — |
NCT02082210CT.gov A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | — | Completed | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01472081CT.gov Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) | — | Completed | — | — | — |
NCT01358721CT.gov Phase I Biomarker Study (BMS-936558) | — | Completed | — | — | — |
NCT00730639CT.gov A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies | — | Completed | — | — | — |
NCT00515697CT.gov A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma | — | Completed | — | — | — |
NCT00441337CT.gov A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Renal Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | Fred Hutchinson Cancer Center | Approved | BB · 69 |
| Sorafenib | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | P4 | BBB |
| Pazopanib | Imbioray (Hangzhou) Biomedicine Co., Ltd. | P4 | BBB |
| Belzutifan | Vall d'Hebron Institute of Oncology | P3 | BBB |
| Cyclosporin A | National Cancer Institute (NCI) | P2 | BB |
| Interferon-Alfa-2A | Central European Society for Anticancer Drug Research | P3 | BB |
| Everolimus | Merck Sharp & Dohme LLC | P4 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P3 | BB |
| Alpha-Interferon | Fuzhou General Hospital | P3 | BB |
+42 more in the Renal Cell Carcinoma cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivolumab in Renal Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-renal-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →